PDCD1 and neoplasm: In the case of immunotherapy, considerations beyond the tumor may also be particularly important; for example, early laboratory studies have shown that the composition of the intestinal microbiota significantly impacts the efficacy of CTLA-4/PD-1 inhibitors [179, 180].